Ranbaxy inks agreement with Gilead sciences
Ranbaxy Laboratories Limited announced that it has entered into an agreement with Gilead Sciences, to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine (FTC) in developing countries, including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.
Under the new agreements, Gilead will provide a technology transfer for manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce overall manufacturing costs.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide, World Health Organization guidelines recommend emtricitabine, as well as tenofovir disoproxil fumarate (TDF), as preferred components of first- and second-line HIV therapy, a company release said.
However, cost is currently a barrier to broadening access to regimens that include emtricitabine when compared to other regimens,including widely used lamivudine (3TC)-based regimens.
The new agreements are designed to enable Gilead's Indian generic partners to produce high volumes of FTC/TDF-based therapies, thereby establishing sustainable price parity to these alternative regimens,it added.